PsA Screening Questionnaire for Psoriatic Arthritis
Trial Summary
The trial information does not specify whether you need to stop taking your current medications.
The Psoriasis Epidemiology Screening Tool (PEST) has shown a high sensitivity of 0.94, meaning it is effective at correctly identifying those with psoriatic arthritis, and a specificity of 0.78, indicating it can also correctly identify those without the condition. The Toronto Psoriatic Arthritis Screen (ToPAS) has been validated and refined to improve its ability to distinguish between those with and without psoriatic arthritis.
12345The PsA Screening Questionnaire, including tools like ToPAS and PEST, is a set of questions used to identify signs of psoriatic arthritis. These questionnaires are non-invasive and generally safe for humans as they involve answering questions rather than medical procedures.
12346The PsA Screening Questionnaire is not a treatment but a tool to help identify psoriatic arthritis in people with psoriasis. It is promising because it helps doctors find the condition early, which can lead to better management and care for patients.
12347Eligibility Criteria
This trial is for adults over 18 with a diagnosis of psoriasis who haven't been diagnosed with Psoriatic Arthritis. Participants should live close to the study site and have not started any treatment for Psoriatic Arthritis.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive a PsA screening questionnaire and are either instructed to talk with their doctor about a rheumatology referral or given direct access to schedule a rheumatologic evaluation.
Follow-up
Participants are monitored for new PsA diagnoses and rheumatologic evaluations, as well as disease severity and activity.